Technical Analysis for FDMT - 4D Molecular Therapeutics, Inc.

Grade Last Price % Change Price Change
D 45.88 -0.26% -0.12
FDMT closed down 0.26 percent on Friday, January 15, 2021, on 33 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical FDMT trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Upper Bollinger Band Touch Strength 0.00%
Shooting Star Candlestick Bearish -0.26%
New 52 Week High Strength -0.26%
Multiple of Ten Bearish Other -0.26%
Up 3 Days in a Row Strength -0.26%
Upper Bollinger Band Touch Strength -0.26%
NR7 Range Contraction 4.15%
Inside Day Range Contraction 10.77%
Older End-of-Day Signals for FDMT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


4D Molecular Therapeutics, Inc. Description

4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Antibodies Emerging Technologies Molecular Biology Gene Therapy Medical Genetics Gene Delivery Fabry Disease Gene Therapy Of The Human Retina Gene Therapy Products

Is FDMT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 50.88
52 Week Low 35.01
Average Volume 174,398
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 41.73
10-Day Moving Average 41.76
Average True Range 4.10
ADX 0.0
+DI 30.24
-DI 12.36
Chandelier Exit (Long, 3 ATRs ) 38.58
Chandelier Exit (Short, 3 ATRs ) 47.31
Upper Bollinger Band 47.88
Lower Bollinger Band 35.59
Percent B (%b) 0.84
BandWidth 29.46
MACD Line 1.37
MACD Signal Line 0.39
MACD Histogram 0.9782
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 51.26
Resistance 3 (R3) 51.65 50.23 50.37
Resistance 2 (R2) 50.23 48.86 50.04 50.07
Resistance 1 (R1) 48.06 48.01 47.35 47.67 49.77
Pivot Point 46.64 46.64 46.29 46.45 46.64
Support 1 (S1) 44.47 45.27 43.76 44.09 41.99
Support 2 (S2) 43.05 44.42 42.86 41.69
Support 3 (S3) 40.88 43.05 41.39
Support 4 (S4) 40.50